Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and outcomes

ID	Age at auto-SCT, y	Sex	Race	Diagnosis, stage	Prior lines of therapy	Disease status prior to auto-SCT	MRD detected after auto-SCT on day 42?	MRD detected on day 100?	Response on day 100	Relapse after auto-SCT and blin	DOR after auto-SCT, mo	Death
1	69	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	Yes	33	No
2	64	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	Yes	8	No
3	65	M	Caucasian	DLBCL, II	3	CR	No	No	CR	Yes	18	No
4	57	F	Caucasian	DLBCL, IV	3	CR	No	No	CR	No	49	No
5	64	M	Caucasian	DLBCL, IV	2	PR	No	No	PD	Yes	5	Yes
6	68	F	Caucasian	Transformed FL, IV	2	CR	No	No	CR	No	37	No
7	74	M	Caucasian	Transformed FL, III	2	PR	Yes	No	CR	Yes	10	Yes
8	74	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	No	45	No
9	74	M	Caucasian	Double hit lymphoma (Bcl-2/MYC), IV	7	CR	No	No	CR	No	37	No
10	53	F	Asian	Transformed FL, IV	4	PR	Yes, below LOD	No	CR	Yes	24	No
11	61	F	Caucasian	DLBCL, IV	2	CR	No	Yes	PD	Yes	4	No
12	65	M	Caucasian	Transformed FL, III	2	CR	No	No	CR	Yes	18	No
13	34	M	Caucasian	DLBCL, IV	2	CR	No	No	CR	Yes	8	Yes
14	67	M	Caucasian	DLBCL, III	2	PR	No	No	CR	Yes	12	Yes

ID	Age at auto-SCT, y	Sex	Race	Diagnosis, stage	Prior lines of therapy	Disease status prior to auto-SCT	MRD detected after auto-SCT on day 42?	MRD detected on day 100?	Response on day 100	Relapse after auto-SCT and blin	DOR after auto-SCT, mo	Death
1	69	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	Yes	33	No
2	64	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	Yes	8	No
3	65	M	Caucasian	DLBCL, II	3	CR	No	No	CR	Yes	18	No
4	57	F	Caucasian	DLBCL, IV	3	CR	No	No	CR	No	49	No
5	64	M	Caucasian	DLBCL, IV	2	PR	No	No	PD	Yes	5	Yes
6	68	F	Caucasian	Transformed FL, IV	2	CR	No	No	CR	No	37	No
7	74	M	Caucasian	Transformed FL, III	2	PR	Yes	No	CR	Yes	10	Yes
8	74	M	Caucasian	Transformed FL, IV	2	CR	No	No	CR	No	45	No
9	74	M	Caucasian	Double hit lymphoma (Bcl-2/MYC), IV	7	CR	No	No	CR	No	37	No
10	53	F	Asian	Transformed FL, IV	4	PR	Yes, below LOD	No	CR	Yes	24	No
11	61	F	Caucasian	DLBCL, IV	2	CR	No	Yes	PD	Yes	4	No
12	65	M	Caucasian	Transformed FL, III	2	CR	No	No	CR	Yes	18	No
13	34	M	Caucasian	DLBCL, IV	2	CR	No	No	CR	Yes	8	Yes
14	67	M	Caucasian	DLBCL, III	2	PR	No	No	CR	Yes	12	Yes

Blin, blinatumomab; DOR, duration of response; LOD, level of detection.